Liraglutide biosimilar (Zhongmei Huadong)

利拉鲁肽生物类似药（中美华东）

Report date: 2024/07/29 16:14:14

Base Information

Drug NameLiraglutide biosimilar (Zhongmei Huadong)
Drug Alias Name利鲁平
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryMainland China
Original Approved Date2023/03/28
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHangzhou Zhongmei Huadong Pharmaceutical Co LtdHangzhou Jiuyuan Gene Biomedical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJulphar (Gulf Pharmaceutical Industries)Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Inactive CompaniesHangzhou Jiuyuan Gene Biomedical Co Ltd
Active IndicationsOverweightObesityDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeA10BJ02
Related LinksN/A